دورية أكاديمية
أعرض في EDS

Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis.

التفاصيل البيبلوغرافية
العنوان: Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis.
المؤلفون: Kalantar-Zadeh K; Division of Nephrology and Hypertension and Transplantation, Harbor-UCLA Medical Center and The Lundquist Institute, Torrance, CA, USA., Ficociello LH; Fresenius Medical Care, Global Medical Office, Waltham, MA, USA., Zhou M; Fresenius Medical Care, Global Medical Office, Waltham, MA, USA., Anger MS; Fresenius Medical Care, Global Medical Office, Waltham, MA, USA. michael.anger@freseniusmedicalcare.com.
المصدر: BMC nephrology [BMC Nephrol] 2024 Jun 17; Vol. 25 (1), pp. 197. Date of Electronic Publication: 2024 Jun 17.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: BioMed Central Country of Publication: England NLM ID: 100967793 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2369 (Electronic) Linking ISSN: 14712369 NLM ISO Abbreviation: BMC Nephrol Subsets: MEDLINE
أسماء مطبوعة: Original Publication: London : BioMed Central, [2000-
مواضيع طبية MeSH: Ferric Compounds*/therapeutic use , Phosphorus*/blood , Peritoneal Dialysis* , Hyperphosphatemia*/drug therapy , Hyperphosphatemia*/etiology , Hyperphosphatemia*/blood , Kidney Failure, Chronic*/therapy , Kidney Failure, Chronic*/blood, Humans ; Middle Aged ; Male ; Retrospective Studies ; Female ; Follow-Up Studies ; Sucrose/therapeutic use ; Drug Combinations ; Aged ; Adult
مستخلص: Background: Hyperphosphatemia is associated with increased morbidity and mortality in patients with end-stage kidney disease (ESKD). Whereas clinical and observational studies have demonstrated the effectiveness of sucroferric oxyhydroxide (SO) in controlling serum phosphorus (sP) in ESKD, data on the real-world impact of switching to SO in patients on peritoneal dialysis (PD) are limited. In this retrospective database analysis, we examine the impact of SO on sP management over a 1-year period among PD patients prescribed SO as part of routine clinical care.
Methods: We analyzed de-identified data from adults on PD in Fresenius Kidney Care clinics who were prescribed SO monotherapy between May 2018 and December 2019 as part of routine clinical management. Changes from baseline in sP levels, phosphate binder (PB) pill burden, and laboratory parameters were evaluated during the four consecutive 91-day intervals of SO treatment.
Results: The mean age of the 402 patients who completed 1 year of SO was 55.2 years at baseline, and they had been on PD for an average of 19.9 months. SO was initiated with no baseline PB recorded in 36.1% of patients, whereas the remaining 257 patients were switched to SO from sevelamer (39.7%), calcium acetate (30.4%), lanthanum (1.2%), ferric citrate (14.0%), or more than one PB (14.8%). Mean sP at baseline was 6.26 mg/dL. After being prescribed SO, the percentage of patients achieving sP ≤ 5.5 mg/dL increased from 32.1% (baseline) to 46.5-54.0% during the 1-year follow-up, whereas the mean number of PB pills taken per day decreased from 7.7 at baseline (among patients on a baseline PB) to 4.6 to 5.4. Serum phosphorus and PB pill burden decreased regardless of changes in residual kidney function over the 12-month period. Similar results were observed for the full cohort (976 patients who either completed or discontinued SO during the 1-year follow-up).
Conclusions: Patients on PD who were prescribed SO as part of routine care for phosphorus management experienced significant reductions in SP and PB pills per day and improvements in sP target achievement, suggesting the effectiveness of SO on SP management with a concurrent reduction in pill burden.
(© 2024. The Author(s).)
References: BMC Nephrol. 2022 Jul 9;23(1):245. (PMID: 35810296)
Int J Nephrol Renovasc Dis. 2013 Oct 04;6:193-205. (PMID: 24133374)
Kidney Int. 2014 Sep;86(3):638-47. (PMID: 24646861)
Int Urol Nephrol. 2014 Jan;46(1):175-82. (PMID: 23591721)
Nephrol Dial Transplant. 2014 Nov;29(11):2092-9. (PMID: 24009281)
Am J Nephrol. 2018;47(3):153-161. (PMID: 29514139)
Int J Nephrol Renovasc Dis. 2022 Apr 11;15:139-149. (PMID: 35431567)
Nephrol Dial Transplant. 2009 May;24(5):1506-23. (PMID: 19001560)
N Engl J Med. 2010 Apr 8;362(14):1312-24. (PMID: 20375408)
Nephrol Dial Transplant. 2023 Jan 23;38(1):193-202. (PMID: 36029279)
Nephrol Dial Transplant. 2000 Nov;15(11):1841-6. (PMID: 11071975)
Nephrol Dial Transplant. 2016 Sep;31(9):1508-14. (PMID: 26908778)
Nephron. 2023;147(10):583-590. (PMID: 36996774)
Kidney Dis (Basel). 2020 Nov;6(6):434-443. (PMID: 33313064)
Clin J Am Soc Nephrol. 2009 Jun;4(6):1089-96. (PMID: 19423571)
Am J Clin Nutr. 2008 Dec;88(6):1511-8. (PMID: 19064510)
Clin Nephrol. 2017 Aug;88(8):59-67. (PMID: 28587714)
Kidney Int Suppl (2011). 2017 Jul;7(1):1-59. (PMID: 30675420)
Clin Kidney J. 2021 Jun 11;14(8):1886-1893. (PMID: 34345411)
Hemodial Int. 2016 Jan;20(1):38-49. (PMID: 25975222)
Perit Dial Int. 2023 Jul;43(4):301-314. (PMID: 35923087)
PLoS One. 2016 Jun 03;11(6):e0156423. (PMID: 27258403)
Nutrients. 2023 Jul 16;15(14):. (PMID: 37513579)
فهرسة مساهمة: Keywords: Hyperphosphatemia; Peritoneal dialysis; Phosphate binder; Phosphorus; Pill burden; Sucroferric oxyhydroxide
المشرفين على المادة: 0 (sucroferric oxyhydroxide)
0 (Ferric Compounds)
27YLU75U4W (Phosphorus)
57-50-1 (Sucrose)
0 (Drug Combinations)
تواريخ الأحداث: Date Created: 20240617 Date Completed: 20240617 Latest Revision: 20240620
رمز التحديث: 20240620
مُعرف محوري في PubMed: PMC11184799
DOI: 10.1186/s12882-024-03633-8
PMID: 38886636
قاعدة البيانات: MEDLINE
الوصف
تدمد:1471-2369
DOI:10.1186/s12882-024-03633-8